{"id":"inegy","safety":{"commonSideEffects":[{"rate":"10.4%","effect":"Vaginal bleeding"},{"rate":"8.5%","effect":"Headache"},{"rate":"6.3%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"INGEY is a combination of norethindrone acetate and ethinyl estradiol, which acts as a selective estrogen receptor modulator.","oneSentence":"Selective estrogen receptor modulator","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:36:17.663Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone replacement therapy"}]},"trialDetails":[{"nctId":"NCT01414192","phase":"","title":"A Study to Design a Model Cohort for Analysis of Dyslipidemia (MK-0653A-204)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-11-15","conditions":"Dyslipidemia, Hypercholesterolemia","enrollment":3215},{"nctId":"NCT00166530","phase":"PHASE4","title":"EASEGO Study: Doubling of Atorvastatin/Simvastatin or INEGY in Patients With Hypercholesterolemia and Coronary Artery Disease(CAD)(0653A-089)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-11","conditions":"Atherosclerosis","enrollment":367},{"nctId":"NCT00202878","phase":"PHASE3","title":"IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-10-17","conditions":"Hypercholesterolemia, Myocardial Infarction","enrollment":18144},{"nctId":"NCT00724477","phase":"","title":"Retrospective Evaluation of the Percentage of Subjects Who Have Reached Their LDL-C Objectives After Treatment With INEGY (Study P05103)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-10","conditions":"Primary Hypercholesterolemia","enrollment":1663},{"nctId":"NCT00461630","phase":"PHASE3","title":"Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2007-01","conditions":"Cardiovascular Disease, Peripheral Arterial Disease, Diabetes Mellitus","enrollment":25673},{"nctId":"NCT01384058","phase":"PHASE4","title":"Effect of Ezetimibe or Simvastatin or Both on Low Densitiy Lipoprotein -Subfractions in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"University Hospital Freiburg","startDate":"2007-11","conditions":"Diabetes Mellitus Type 2, Hypercholesterolemia","enrollment":41},{"nctId":"NCT01424891","phase":"NA","title":"Effects on NF-κB Activity: High Dose Simvastatin Versus Combination Therapy With Ezetimibe","status":"COMPLETED","sponsor":"Heidelberg University","startDate":"2004-04","conditions":"Type 2 Diabetes, Inflammation","enrollment":31}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SCH 465981"],"phase":"phase_2","status":"active","brandName":"INEGY","genericName":"INEGY","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Selective estrogen receptor modulator Used for Hormone replacement therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}